西罗莫司和 mTOR 抑制剂：实体器官移植中不良反应及特定管理的综述。
Sirolimus and mTOR Inhibitors: A Review of Side Effects and Specific Management in Solid Organ Transplantation.
机构信息
Clinical Pharmacology & Center of Clinical Investigation Paris-Est, Sorbonne Université, AP-HP, INSERM, Paris, France.
Service de chirurgie cardiaque, Institut de Cardiologie, AP-HP, Pitié-Salpétrière University Hospital, ICAN, INSERM, Sorbonne Université, 47-53 Boulevard de l'Hopital, 75013, Paris, France.
出版信息
Drug Saf. 2019 Jul;42(7):813-825. doi: 10.1007/s40264-019-00810-9.
Inhibitors of mechanistic target of rapamycin (mTOR inhibitors) are used as antiproliferative immunosuppressive drugs and have many clinical applications in various drug combinations. Experience in transplantation studies has been gained regarding the side effect profile of these drugs and the potential benefits and limitations compared with other immunosuppressive agents. This article reviews the adverse effects of mTOR inhibitors in solid organ transplantation, with special attention given to mechanisms hypothesized to cause adverse events and their management strategies.
雷帕霉素靶蛋白（mTOR）抑制剂被用作抗增殖免疫抑制剂，在各种药物组合中有许多临床应用。关于这些药物的副作用特征以及与其他免疫抑制剂相比的潜在益处和局限性，在移植研究方面已经有了相关经验。本文综述了 mTOR 抑制剂在实体器官移植中的不良反应，特别关注了假设导致不良事件的机制及其管理策略。
Zotero 插件